18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Summary

The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.

Conditions

• Adult Giant Cell Glioblastoma
• Adult Glioblastoma
• Adult Gliosarcoma
• Male Breast Cancer
• Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
• Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
• Recurrent Adult Brain Tumor
• Recurrent Basal Cell Carcinoma of the Lip
• Recurrent Colon Cancer
• Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
• Recurrent Hypopharyngeal Cancer
• Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
• Recurrent Laryngeal Cancer
• Recurrent Lip and Oral Cavity Cancer
• Recurrent Lymphoepithelioma of the Nasopharynx
• Recurrent Lymphoepithelioma of the Oropharynx
• Recurrent Metastatic Squamous Neck Cancer With Occult Primary
• Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
• Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
• Recurrent Nasopharyngeal Cancer
• Recurrent Non-small Cell Lung Cancer
• Recurrent Oropharyngeal Cancer
• Recurrent Pancreatic Cancer
• Recurrent Paranasal Sinus and Nasal Cavity Cancer
• Recurrent Rectal Cancer
• Recurrent Renal Cell Cancer
• Recurrent Salivary Gland Cancer
• Stage IIIA Breast Cancer
• Stage IIIA Non-small Cell Lung Cancer
• Stage IIIB Breast Cancer
• Stage IIIB Non-small Cell Lung Cancer
• Stage IIIC Breast Cancer
• Stage IV Breast Cancer
• Stage IV Non-small Cell Lung Cancer
• Stage IV Pancreatic Cancer
• Stage IV Renal Cell Cancer
• Stage IVA Colon Cancer
• Stage IVA Rectal Cancer
• Stage IVA Salivary Gland Cancer
• Stage IVB Colon Cancer
• Stage IVB Salivary Gland Cancer
• Stage IVC Salivary Gland Cancer
• Tongue Cancer
• Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

18F-fludeoxyglucose (18F-FDG)

18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan

DRUG

18F-FPPRGD2

18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Sanjiv Sam Gambhir

  lead OTHER

Principal Investigators

• Sanjiv Gambhir, MD, PhD · Stanford University

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-03-04

Primary Completion

2016-12-07

Completion

2019-04-30

FDA Drug

Yes

Countries

• United States

Study Locations